Searched for
ONCOLOGY TRIALS
AstraZeneca 'magic' faces rare test after trial failure, share slideAstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted...- Match Your AI Strategy to Your Organization’s RealityArtificial intelligence is often hailed as a game changer, but too many firms discover that their bold AI pilots collapse when their operat...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Infosys-backed 4baseCare raises Rs 128 crore, plans to take its cancer testing platform globalPrecision oncology startup 4baseCare has raised Rs 128 crore. This funding will expand its genomics labs globally and scale its AI platform...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Johnson & Johnson prostate cancer drug reduces risk of cancer spread and death in late-stage studyThe study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have lit...
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
- Could space-grown stem cells unlock faster cancer treatments and revolutionize organ regeneration breakthroughs? NASA’s ISS experiments are revealing surprising answers about the power of microgravity medicineSpace stem cell research is rapidly changing cancer treatment and regenerative medicine worldwide. Scientists aboard the International Spac...
- Who is Shamir Chandran? Indian-origin cancer specialist doctor banned in UK says, ‘I will never work in that country again’Shamir Chandran, a cancer specialist doctor of Indian origin, has been banned from practicing medicine in Britain. He was convicted of cont...
- Novartis sharpening India strategy as a pure-play innovatorNovartis India country president and managing director Amitabh Dube said India is gradually moving beyond its traditional role as a clinica...
- Roche brings 7-minute lung cancer shot to IndiaRoche Pharma India introduces a new injectable immunotherapy for lung cancer. This treatment takes only seven minutes, a significant reduct...
- Roche Pharma launches India’s first 7-minute injectable immunotherapy for lung cancerRoche Pharma has introduced Tecentriq, India's first under-the-skin immunotherapy for lung cancer. This new injection takes about seven min...
- MOC Cancer Care raises $18 million from Elevation CapitalThe funds will be used for expanding operations, opening new centres, and diversifying the range of services offered, said the Mumbai-based...
- Aurigene reports promising phase-1 data for its CAR-T therapy against myelomaAurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with mul...
- ICMR nod to pvt hospital to try plasma therapy for COVID-19 patientsThis was stated by the Drugs Controller General of India in a letter to to HCG Bangalore Institute of Oncology Speciality Centre. The permi...
- New treatment for ovarian cancer developedDoctors said the new treatment can improve response rates (increase the rate of tumour shrinkage) and delay cancer progression.
- India's oncology market to touch Rs 3,831-crore by 2017: StudyThe oncology market in India is growing at 20 per cent annually and is expected to touch Rs 3,831 crore by 2017.
- Veeda Oncology acquires Biologie et IndustrieVeeda Oncology on Tuesday said it has completed the acquisition of Paris-based Biologie et Industrie bolstering its presence in the segment.
- Dabur working on generic products launch in USDabur Pharma is working on 17 new chemical entities and will launch 12 generic products in the US by the next year.
Load More
